Sort
34,240 grants matching “atherosclerosis”
Managing Atherosclerosis by Modulating HDL Function
$649,985M. Reza Ghadiri · Scripps Research Institute, The · R01 · FY2014 · HL
**AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** CHRONIC INFLAMMATION IS AN IMPORTANT FEATURE OF CARDIOMETABOLIC DISEASES, INCLUDING CARDIOVASCULAR DISEASE, THE MAJOR CAUSE OF MORBIDITY AND MORTALITY IN THE U.S. CHRONIC INFLAMMATION OCCURS WHEN THE BODY'S ABILITY TO RESOLVE INFLAMMATION IS WEAKENED. THE RESOLUTION OF INFLAMMATION IS PROMOTED BY LIPID MOLECULES DERIVED FROM THE OMEGA-3 FATTY ACIDS EPA AND DHA PRESENT IN FISH AND FISH OIL AND CALLED SPECIALIZED PRO-RESOLVING LIPID MEDIATORS (SPMS). WESTERN DIET HAS BEEN SHOWN TO CAUSE ALTERATIONS IN GUT MICROBIOTA COMPOSITION AND FUNCTION, INFLAMMATION, AND CARDIOVASCULAR DISEASE BOTH IN HUMANS AND IN MICE. HOWEVER, WHETHER OMEGA-3 FA-DERIVED SPMS CAN PREVENT THE WESTERN DIET-INDUCED ALTERATIONS IN GUT MICROBIOTA IS CURRENTLY NOT KNOWN. OUR STUDY WILL DETERMINE THE IMPACT OF THE CHANGES IN GUT MICROBIOTA CAUSED BY OMEGA-3 FA-DERIVED SPMS ON INFLAMMATION AND ATHEROSCLEROSIS BY USING MICE THAT LACK THE ENZYME INVOLVED IN THE CONVERSION OF OMEGA-3 FATTY ACIDS TO SPMS. BY COMPARING THE EFFECTS ON GUT MICROBIOTA AND INFLAMMATION IN CONTROL MICE AND IN MICE THAT CANNOT PRODUCE SPMS RECEIVING OMEGA-3 SUPPLEMENTATION, OUR STUDY WILL PROVIDE IMPORTANT KNOWLEDGE ON THE ROLE OF SPMS ON GUT MICROBIOTA AND LEAD TO THE DEVELOPMENT OF THERAPEUTIC INTERVENTIONS FOR THE PREVENTION OF GUT MICROBIOTA ALTERATIONS, INFLAMMATION, AND CARDIOMETABOLIC DISEASES.
$649,842Trustees Of Tufts College · · FY2022 · National Institute of Food and Agriculture
** AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** TRIMETHYLAMINE N-OXIDE (TMAO) IS A HARMFUL METABOLITE DERIVED FROM GUT BACTERIA. CIRCULATING LEVELS OF TMAO ARE POSITIVELY ASSOCIATED WITH ATHEROSCLEROSIS RISK. CARDIOVASCULAR DISEASE, INCLUDING ATHEROSCLEROSIS, IS THE LEADING CAUSE OF DEATH WORLDWIDE. NO DRUGS ARE APPROVED TO LOWER TMAO. STRATEGIES SUCH AS DIET REPRESENT OUR BEST BET FOR CONTROLLING TMAO. DIETARY PHENOLICS HAVE SHOWN POTENTIAL FOR BENEFICIALLY ALTERING GUT BACTERIAL COMMUNITIES AND METABOLISM. ONE SUCH COMPOUND IS CHLOROGENIC ACID, FOUND IN FOODS SUCH AS BLUEBERRIES. OUR PRELIMINARY DATA SUGGEST THAT CHLOROGENIC ACID-RICH BLUEBERRIES REDUCE TMO LEVELS IN VIVO. HOWEVER, CHLOROGENIC ACID CONTENT VARIES WIDELY IN BLUEBERRY CULTIVARS. WE HYPOTHESIZE THAT THE CHLOROGENIC ACID CONTENT OF BLUEBERRIES CORRESPONDS TO THEIR TMAO-LOWERING AND CARDIOPROTECTIVE EFFECTS. WE PROPOSE TO USE IN VITRO AND IN VIVO STUDIES TO DETERMINE THE RELATIONSHIP BETWEEN THE CHLOROGENIC ACID CONTENT OF BLUEBERRIES AND THEIR TMAO-LOWERING AND ANTI-ATHEROSCLEROSIS ACTIVITIES. THE RATIONALE FOR THIS WORK IS THAT UNDERSTANDING WHETHER THE CHLOROGENIC ACID CONTENT OF FOODS CORRESPOND TO THEIR EFFICACY FOR LOWERING TMAO CAN LEAD TO HEALTHIER DIETARY PATTERNS IN AT-RISK INDIVIDUALS AND THE POPULATION, AND THAT BREEDERS CAN USE THESE DATA TO BREED CHLOROGENIC ACID-RICH CULTIVARS. THE LONG-TERM EFFECTS OF SUCH PATTERNS MAY REDUCE CARDIOVASCULAR DISEASE BURDEN AND INCREASE QUALITY OF LIFE AT THE INDIVIDUAL AND POPULATION LEVELS. THIS APPLICATION RESPONDS TO PROGRAM AREA PRIORITY 3D (FOOD AND HUMAN HEALTH) BY INVESTIGATING THE IMPACT OF FOOD COMPONENTS (BLUEBERRY CHLOROGENIC ACID) ON THE GUT MICROBIOME AND ITS METABOLITES (BACTERIAL-DERIVED TMAO) AND HOW THIS RELATES TO HUMAN HEALTH (PREVENTION OF ATHEROSCLEROSIS).
$649,753North Carolina State University · · FY2024 · National Institute of Food and Agriculture
Efflux proteins and insulin resistance in atherogenesis
$649,713David P Hajjar · Weill Medical Coll Of Cornell Univ · P01 · FY2007 · HL
Health Outcomes of Discontinuing Aspirin in Older Adults with Alzheimer's Disease and Related Dementias
$649,603Carolyn Timberlake Thorpe · Univ Of North Carolina Chapel Hill · R01 · FY2023 · AG
Longitudinal Study of Predictors and Consequences of Chronic Kidney Disease
$649,600Brad C Astor · Johns Hopkins University · R01 · FY2010 · DK
The role of Chlamydia pneumoniae infection in Alzheimer's Disease
$649,583Timothy Robert Crother · Cedars-Sinai Medical Center · R01 · FY2025 · AG
Atherosclerosis, Prostaglandin Inhibition and Checkpoint Blockade
$649,492Garret A Fitzgerald · University Of Pennsylvania · R01 · FY2020 · HL
The Anti-angiogenic VEGF165b and VEGFR1 Signaling in Peripheral Artery Disease
$649,402Brian H Annex · Augusta University · R01 · FY2020 · HL
Mechanism of the coronary heart disease association at chromosome 6q23.2
$649,375Thomas None Quertermous · Stanford University · R01 · FY2013 · HL
Precursors of Stroke Incidence and Prognosis
$649,162Philip A Wolf · Boston University Medical Campus · R01 · FY2008 · NS
Targeting RIPK3 in Age-Related Inflammation and Injury
$648,995Alexei Degterev · Tufts University Boston · R56 · FY2018 · AG
PeRiodontal treatment to Eliminate Minority InEquality and Rural disparities in Stroke (PREMIERS)
$648,978Souvik Sen · University Of South Carolina At Columbia · R01 · FY2019 · MD
The Risk of Myocardial Infarction in Patients with Psoriasis
$648,965Joel M Gelfand · University Of Pennsylvania · R01 · FY2013 · HL
Bayesian machine learning for causal inference with incomplete longitudinal covariates and censored survival outcomes
$648,965Liangyuan Hu · Rutgers Biomedical And Health Sciences · R01 · FY2024 · HL
Dynamics of the cellular and molecular architecture of human pulmonary TB granulomas
$648,711Robert L Modlin · University Of California Los Angeles · R01 · FY2024 · AI
Variant Determinants of African American Limb Pathology in Peripheral Arterial Disease
$648,656Joseph Matthew McClung · East Carolina University · R01 · FY2022 · HL
Critical Mediators of Inflammation Resolution and Immune Memory in Atherosclerosis
$648,535Amanda C Doran · Vanderbilt University Medical Center · R01 · FY2022 · HL
Metal Exposure and Early Cardiovascular Risk in Adult E-Cigarette Users
$648,515Ana Navas-Acien · Columbia University Health Sciences · R01 · FY2024 · ES
Novel strategies to understand, predict, and prevent vascular toxicity of targeted CML therapies
$648,472Iris Z Jaffe · Tufts Medical Center · R01 · FY2024 · HL
Loss of insulin signaling across functional pancreas compartments as a major pathogenic mechanism underlying diabetic exocrine pancreatopathy
$648,358Alejandro Caicedo Vierkant · University Of Miami School Of Medicine · R01 · FY2024 · DK
Elastic, Degradable Vascular Grafts with Helical Microfibers
$648,267Yadong Wang · Cornell University · R01 · FY2021 · HL
Longitudinal Study of HIV and Aging in Brazil
$648,264Jessica L Castilho · Vanderbilt University Medical Center · R01 · FY2022 · AG
IL-35 inhibits gut microbiota-produced uremic toxin-accelerated endothelial cell activation
$648,249Xiao-Feng Yang · Temple Univ Of The Commonwealth · R01 · FY2021 · HL
IL-35 inhibits gut microbiota-produced uremic toxin-accelerated endothelial cell activation
$648,249Xiao-Feng Yang · Temple Univ Of The Commonwealth · R01 · FY2022 · HL